Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell NHL
NCT02207062Phase 2Completed
- Sponsor
- University of Washington
- Start
- Oct 2014
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in B-cell non-Hodgkin lymphoma, sponsored by University of Washington. Started Oct 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02207062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207062.